Abstract #0737

Hippocampal Choline Level Predicts Symptomatic Improvement with Agomelatine in Major Depressive Disorder: A 3 Tesla Single Voxel Spectroscopy Study

Najib Allali¹,², Romain Valabregue², Malgorzata MarjanskaA³,⁴, Pauline Delaveau¹, ric Bardinet², Maritza Jabourian⁵, Judith LAREDO⁵, Philippe Fossati¹,⁶, Stphane Lehricy²,⁷

¹USR 3246, CNRS, Paris, le-de-France, France; ²Centre de Neuroimagerie de Recherche - CENIR, Institut du Cerveau et de la Moelle pinire - ICM, Paris, le-de-France, France; ³Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, United States; ⁴Department of Radiology, University of Minnesota, Minneapolis, MN, United States; ⁵Institut de Recherches Internationales Servier - IRIS, Courbevoie, le-de-France, France; ⁶Psychiatry, APHP - GH Piti Salptrire, Paris, le-de-France, France; ⁷UMR-S975 ; Inserm, U975 ; CNRS, UMR 7225, Paris, France, CRICM, Universit Pierre et Marie Curie, Paris, le-de-France, France

In this study, we sought to identify spectroscopic correlates of depressive state and of response to Agomelatine, a new antidepressant with melatonin agonist and 5-HT2C antagonist properties.